🧬 Bimagrumab

What Is Bimagrumab?

Bimagrumab is a fully human, recombinant monoclonal antibody (IgG1) that targets activin type II A and B receptors (ActRIIA and ActRIIB) . It was originally developed by Novartis and is now being advanced by Eli Lilly .

Unlike GLP‑1 receptor agonists, which work primarily through appetite suppression, bimagrumab acts directly on skeletal muscle and adipose tissue to promote muscle growth and reduce fat mass simultaneously . It is being investigated for obesity, sarcopenia, and muscle‑wasting conditions—and has emerged as a potential muscle‑sparing adjunct to incretin‑based weight‑loss therapies .

Mechanism of Action

Bimagrumab blocks the signaling of myostatin, activin A, and other TGF‑β superfamily ligands through the ActRIIA and ActRIIB receptors . This dual receptor blockade has two key effects:

• Muscle: Suppresses SMAD2/3 signaling, releasing the brake on muscle protein synthesis. Preclinical murine models showed 10–15% increases in muscle fiber size .
• Adipose Tissue: Activin signaling via ActRII‑ALK7 pathways regulates abdominal obesity. Blocking this signaling increases lipid mobilization and lipolysis, leading to fat mass reduction .
• mTOR Activation: Bimagrumab activates mTOR signaling, promoting muscle growth and preventing the muscle breakdown that often accompanies calorie restriction .

This dual effect—muscle gain and fat loss—is what distinguishes bimagrumab from other obesity treatments . It is also why it is being studied in combination with GLP‑1 agonists like semaglutide and tirzepatide .

BELIEVE Trial · Phase 2 Data

The BELIEVE Phase 2b trial (NCT05616013) evaluated bimagrumab alone and in combination with semaglutide in 507 adults with obesity (without diabetes) over 48 weeks, with a 24‑week extension .

📊 Key Results (72 Weeks)

• Bimagrumab 30 mg/kg alone: 10.8% weight loss; 100% from fat; +2.5% lean mass .
• Semaglutide 2.4 mg alone: 15.7% weight loss; 71.5% from fat; −7.4% lean mass .
• High‑dose combination (30 mg/kg + 2.4 mg): 22.1% weight loss; 92.9% from fat; −2.9% lean mass .
• Waist circumference: High‑dose combination achieved −21.7 cm reduction—described as “8½ holes on your belt” .
• Adiponectin: Increased to 37.9 µg/mL in the combination group (vs. 7.2 µg/mL with semaglutide alone), suggesting improved metabolic health .

At week 48, the primary endpoint showed high‑dose combination achieved −17.8 kg weight loss vs. −14.2 kg for semaglutide alone (P = 0.039) . By week 72, continued improvements were observed .

Muscle Preservation: The Key Differentiator

One of the most significant findings from the BELIEVE trial is the dramatic difference in body composition:

• Semaglutide alone: ~25–40% of weight loss comes from lean mass (muscle and organs) . This is consistent with calorie‑restriction‑induced weight loss.
• Bimagrumab alone: 100% of weight loss came from fat, with a net gain in muscle mass .
• Combination therapy: 92.9% of weight loss from fat, with minimal muscle loss (2.9%)—a significant improvement over semaglutide alone (71.5% fat loss, 7.4% muscle loss) .

This muscle‑sparing effect is clinically meaningful because:

• Muscle loss reduces metabolic rate, making weight regain more likely .
• Muscle is critical for physical function, glucose disposal, and overall metabolic health .
• Patients with sarcopenic obesity—a growing population—could particularly benefit from a therapy that builds muscle while losing fat .

Safety & Side Effects

Bimagrumab has a distinct safety profile compared to GLP‑1 agonists . Common adverse events include:

• Muscle spasms: Occurred in 46–74% of bimagrumab‑treated patients—the most common side effect . This led to discontinuation in some patients .
• Diarrhea: 41–49% of bimagrumab patients .
• Acne: 34–44% of bimagrumab patients .
• Injection‑site reactions, nausea, and headache were also reported .

Serious adverse events were uncommon, with no deaths reported in the BELIEVE trial . However, discontinuation rates due to adverse events were higher in the bimagrumab groups (14–21%) than in the semaglutide groups (3.6–8.8%) .

Long‑term safety data are still being collected. A 2‑year extension of the RESILIENT trial (in sIBM) showed a good safety profile with no major organ toxicity .

Regulatory Status

Bimagrumab is not yet FDA‑approved for any indication . It remains an investigational drug, currently in Phase 2/3 development led by Eli Lilly .

• Orphan drug designations: Bimagrumab received orphan drug designation for sporadic inclusion body myositis (sIBM) from the FDA and EMA .
• Phase 3 plans: Lilly has announced plans to advance bimagrumab into Phase III trials for obesity .
• Ongoing trials: A Phase 2 trial combining tirzepatide with bimagrumab is currently recruiting (NCT05933499), aiming to demonstrate the additive benefits of the ActRII blocker with dual incretin therapy .

Bimagrumab represents a fundamentally new approach to obesity and body composition management. By directly targeting the ActRII pathway, it can promote muscle growth while reducing fat mass—addressing the key limitation of calorie‑restriction‑based weight loss. The BELIEVE Phase 2 data are encouraging, showing that bimagrumab alone can achieve fat‑exclusive weight loss, and in combination with semaglutide, it enhances total weight loss while preserving muscle. However, it remains investigational, with a distinct side effect profile and no FDA approval. For clinicians and patients, bimagrumab is a therapy to watch—but not yet a therapy to use outside of clinical trials.

❓ FAQs About Bimagrumab

✧ Written in service of evidence‑based medicine and scientific curiosity ✧